Literature DB >> 20636480

Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients.

S A Pergam1, C W Forsberg, M J Boeckh, C Maynard, A P Limaye, A Wald, N L Smith, B A Young.   

Abstract

BACKGROUND: Immunosuppressed patients are at increased risk for herpes zoster (HZ), but incidence in solid organ transplant (SOT) recipients has varied in multiple studies. To assess incidence of HZ, we examined patients who underwent SOT and received follow-up care within the large multicenter US Department of Veteran's Affairs healthcare system.
METHODS: Incident cases of HZ were determined using ICD-9 coding from administrative databases. A multivariable Cox proportional hazards model, adjusted for a priori risk factors, was used to assess demographic factors associated with development of HZ.
RESULTS: Among the 1077 eligible SOT recipients, the cohort-specific incidence rate of HZ was 22.2 per 1000 patient-years (95% confidence interval [CI], 18.1-27.4). African Americans (37.6 per 1000 [95% CI, 25.0-56.6]) and heart transplants recipients (40.0 per 1000 [95% CI, 23.2-68.9]) had the highest incidence of HZ. Patients transplanted between 2005 and 2007 had the lowest incidence (15.3 per 1000 [95% CI, 8.2-28.3]). In a multivariable model, African Americans (hazard ratio [HR] 1.88; 95% CI: 1.12, 3.17) and older transplant recipients (HR 1.13; 95% CI: 1.01, 1.27 [per 5-year increment]) had increased relative hazards of HZ.
CONCLUSIONS: These data demonstrate that HZ is a common infectious complication following SOT. Future studies focused on HZ prevention are needed in this high-risk population.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 20636480      PMCID: PMC2976841          DOI: 10.1111/j.1399-3062.2010.00547.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  60 in total

Review 1.  Herpes zoster.

Authors:  David W Wareham; Judith Breuer
Journal:  BMJ       Date:  2007-06-09

2.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately.

Authors:  Sebastian Schneeweiss; Ari Robicsek; Richard Scranton; Dan Zuckerman; Daniel H Solomon
Journal:  J Clin Epidemiol       Date:  2006-12-18       Impact factor: 6.437

Review 3.  Prevention of VZV infection in immunosuppressed patients using antiviral agents.

Authors:  Michael Boeckh
Journal:  Herpes       Date:  2006-11

4.  The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases.

Authors:  J R Kramer; J A Davila; E D Miller; P Richardson; T P Giordano; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2007-11-08       Impact factor: 8.171

5.  Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.

Authors:  Hugo R Rosen; Scott J Weston; KyungAh Im; Huiying Yang; James R Burton; Henry Erlich; Jared Klarquist; Steven H Belle
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

6.  One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.

Authors:  Veronique Erard; Katherine A Guthrie; Cara Varley; Judson Heugel; Anna Wald; Mary E D Flowers; Lawrence Corey; Michael Boeckh
Journal:  Blood       Date:  2007-05-21       Impact factor: 22.113

Review 7.  Racial and ethnic disparities in the VA health care system: a systematic review.

Authors:  Somnath Saha; Michele Freeman; Joahd Toure; Kimberly M Tippens; Christine Weeks; Said Ibrahim
Journal:  J Gen Intern Med       Date:  2008-02-27       Impact factor: 5.128

8.  Incidence and clinical characteristics of herpes zoster after lung transplantation.

Authors:  Oriol Manuel; Deepali Kumar; Lianne G Singer; Isabel Cobos; Atul Humar
Journal:  J Heart Lung Transplant       Date:  2008-01       Impact factor: 10.247

9.  Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Yuki Asano-Mori; Yoshinobu Kanda; Kumi Oshima; Shinichi Kako; Akihito Shinohara; Hideki Nakasone; Hiroyuki Sato; Takuro Watanabe; Noriko Hosoya; Koji Izutsu; Takashi Asai; Akira Hangaishi; Toru Motokura; Shigeru Chiba; Mineo Kurokawa
Journal:  Am J Hematol       Date:  2008-06       Impact factor: 10.047

10.  Ethnicity as a predictor of graft longevity and recipient mortality in heart transplantation.

Authors:  O Cohen; D De La Zerda; R E Beygui; D Hekmat; H Laks
Journal:  Transplant Proc       Date:  2007-12       Impact factor: 1.066

View more
  26 in total

1.  Underimmunization of the solid organ transplant population: An urgent problem with potential digital health solutions.

Authors:  Amy G Feldman; Katherine Atkinson; Kumanan Wilson; Deepali Kumar
Journal:  Am J Transplant       Date:  2019-10-28       Impact factor: 8.086

2.  Robust gene expression changes in the ganglia following subclinical reactivation in rhesus macaques infected with simian varicella virus.

Authors:  Nicole Arnold; Christine Meyer; Flora Engelmann; Ilhem Messaoudi
Journal:  J Neurovirol       Date:  2017-03-20       Impact factor: 2.643

3.  Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.

Authors:  Laura P Hurley; Sean T O'Leary; Kathleen Dooling; Tara C Anderson; Lori A Crane; Jessica R Cataldi; Michaela Brtnikova; Brenda L Beaty; Carol Gorman; Angela Guo; Megan C Lindley; Allison Kempe
Journal:  J Gen Intern Med       Date:  2022-07-06       Impact factor: 6.473

4.  Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.

Authors:  M D Long; C Martin; R S Sandler; M D Kappelman
Journal:  Aliment Pharmacol Ther       Date:  2012-12-13       Impact factor: 8.171

5.  Incidence and risk factors for herpes zoster following heart transplantation.

Authors:  S Koo; L S Gagne; P Lee; P P Pratibhu; L M James; M M Givertz; F M Marty
Journal:  Transpl Infect Dis       Date:  2013-10-23       Impact factor: 2.228

6.  Varicella zoster virus in solid organ transplantation.

Authors:  S A Pergam; A P Limaye
Journal:  Am J Transplant       Date:  2013-03       Impact factor: 8.086

7.  Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.

Authors:  Susannah L McKay; Angela Guo; Steven A Pergam; Kathleen Dooling
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

8.  Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients.

Authors:  Cedric Hirzel; Arnaud G L'Huillier; Victor H Ferreira; Tina Marinelli; Terrance Ku; Matthew Ierullo; Congrong Miao; D Scott Schmid; Stephen Juvet; Atul Humar; Deepali Kumar
Journal:  Am J Transplant       Date:  2021-03-06       Impact factor: 9.369

Review 9.  Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.

Authors:  Marta López-Fauqued; Maribel Co-van der Mee; Adriana Bastidas; Pierre Beukelaers; Alemnew F Dagnew; Juan Jose Fernandez Garcia; Anne Schuind; Fernanda Tavares-da-Silva
Journal:  Drug Saf       Date:  2021-06-11       Impact factor: 5.606

10.  Epidemiology and risk factors for varicella zoster virus reactivation in heart transplant recipients.

Authors:  Ricardo M La Hoz; Ashley Wallace; Nicolas Barros; Donglu Xie; Linda S Hynan; Terrence Liu; Christina Yek; Scott Schexnayder; Justin L Grodin; Sonia Garg; Mark H Drazner; Matthias Peltz; Robert W Haley; David E Greenberg
Journal:  Transpl Infect Dis       Date:  2020-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.